Ovid Therapeutics Inc. (OVID)
| Market Cap | 156.68M |
| Revenue (ttm) | 6.91M |
| Net Income (ttm) | -75.98M |
| Shares Out | 59.41M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.47 |
| Previous Close | $2.57 |
| Change ($) | -0.10 |
| Change (%) | -3.89% |
| Day's Open | 2.61 |
| Day's Range | 2.46 - 2.65 |
| Day's Volume | 1,477,735 |
| 52-Week Range | 2.03 - 8.24 |
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...
Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. The post Ovid Therapeutics News: Why OVID Stock Is Plunging 55% To...
The company reported disappointing results from a late-stage clinical trial.
NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...
Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.
Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinic...
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ne...
NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare n...
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rar...
NEW YORK and OSAKA, Japan, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biop...
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
Ovid Therapeutics Is Quickly Approaching A Transformational Valuation Milestone
Here are the best biotech stocks for investors looking for market-beating performance.
NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the live...
One analyst thinks the stock still has significant upside. Is that enough to justify its price?
NEW YORK and ROME, July 13, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID, hereinafter “Ovid”), a biopharmaceutical company committed to developing medicines that transform t...
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
Ovid Therapeutics (OVID) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
Investors need to pay close attention to Ovid Therapeutics (OVID) stock based on the movements in the options market lately.
NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
When choosing cheap stocks to invest in you don't always have to sacrifice quality. Here are four high-quality companies that are affordable.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare ...
Ovid Advances Fragile X Syndrome Drug Forward; Multiple Catalysts Still Expected In 2020
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare n...
Top Ranked Momentum Stocks to Buy for April 22nd
The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of th...
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.
Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings. The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared ...
Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team
These stocks come from a variety of industries, but all have positive catalysts in their futures. Buy these cheap stocks now while you can.
As of late, it has definitely been a great time to be an investor Ovid Therapeutics.
NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rar...
Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rar...
Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Despite this truncated trading week, Tuesday was a breakout day for a few biotech companies.
Shares have lost roughly 87% since IPO and fallen by more than 80% since my last update article.
Ovid Therapeutics Inc. shares have been on a steady downtrend since Aug. 6, 2018, when it released topline data from a Phase 2 study dubbed STARS that evaluated its OV101 for treating a geneti...
About OVID
Ovid Therapeutics, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficie... [Read more...]
| Industry Biotechnology | IPO Date May 5, 2017 |
| CEO Jeremy Levin | Employees 65 |
| Stock Exchange NASDAQ | Ticker Symbol OVID |
Analyst Forecasts
According to 7 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 142.91% from the latest price.